Drug
Colistimethate sodium (CMS)
Colistimethate sodium (CMS) is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Completed1
Recruiting1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (50.0%)
N/A1 (50.0%)
Trials by Status
completed133%
recruiting133%
not_yet_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingnot_applicable
Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial
NCT06834971
not_yet_recruiting
Comparing Tigecycline Vs. Colistimethate in CNS Infections
NCT06702943
completedphase_3
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
NCT02452047
Clinical Trials (3)
Showing 3 of 3 trials
NCT06834971Not Applicable
Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial
NCT06702943
Comparing Tigecycline Vs. Colistimethate in CNS Infections
NCT02452047Phase 3
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3